JP2017002083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017002083A5 JP2017002083A5 JP2016196955A JP2016196955A JP2017002083A5 JP 2017002083 A5 JP2017002083 A5 JP 2017002083A5 JP 2016196955 A JP2016196955 A JP 2016196955A JP 2016196955 A JP2016196955 A JP 2016196955A JP 2017002083 A5 JP2017002083 A5 JP 2017002083A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- nanoparticles
- blood vessels
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 62
- 210000004204 Blood Vessels Anatomy 0.000 claims 16
- 239000002105 nanoparticle Substances 0.000 claims 15
- 102100001249 ALB Human genes 0.000 claims 9
- 101710027066 ALB Proteins 0.000 claims 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 9
- 229940050528 albumin Drugs 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- 229960002930 sirolimus Drugs 0.000 claims 9
- 210000001367 Arteries Anatomy 0.000 claims 6
- 230000002792 vascular Effects 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000000265 Leukocytes Anatomy 0.000 claims 2
- 210000001147 Pulmonary Artery Anatomy 0.000 claims 2
- 230000001737 promoting Effects 0.000 claims 2
- 206010002383 Angina pectoris Diseases 0.000 claims 1
- 206010003119 Arrhythmia Diseases 0.000 claims 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 210000001627 Cerebral Arteries Anatomy 0.000 claims 1
- 210000004351 Coronary Vessels Anatomy 0.000 claims 1
- 210000002414 Leg Anatomy 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 210000002254 Renal Artery Anatomy 0.000 claims 1
- 210000003462 Veins Anatomy 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
Claims (37)
- 血管におけるネガティブリモデリングを阻害する必要のある個体において血管におけるネガティブリモデリングを阻害するための組成物であって、ラパマイシンおよびアルブミンを含むナノ粒子の有効量を含み、該組成物は、血管壁内への注射によって該個体に投与されることを特徴とする、組成物。
- 血管における血管線維症を阻害する必要のある個体において血管における血管線維症を阻害するための組成物であって、ラパマイシンおよびアルブミンを含むナノ粒子の有効量を含み、該組成物は、血管壁内への注射によって該個体に投与されることを特徴とする、組成物。
- 前記血管線維症が中膜血管線維症または外膜線維症である、請求項2に記載の組成物。
- 血管におけるポジティブリモデリングを促進する必要のある個体において血管におけるポジティブリモデリングを促進するための組成物であって、ラパマイシンおよびアルブミンを含むナノ粒子の有効量を含み、該組成物は、血管壁内への注射によって該個体に投与されることを特徴とする、組成物。
- 血管における外膜血管を低減する必要のある個体において血管における外膜血管を低減するための組成物であって、ラパマイシンおよびアルブミンを含むナノ粒子の有効量を含み、該組成物は、血管壁内への注射によって該個体に投与されることを特徴とする、組成物。
- 血管における外膜の白血球を低減する必要のある個体において血管における外膜の白血球を低減するための組成物であって、ラパマイシンおよびアルブミンを含むナノ粒子の有効量を含み、該組成物は、血管壁内への注射によって該個体に投与されることを特徴とする、組成物。
- 前記血管が動脈である、請求項1から6のいずれか一項に記載の組成物。
- 前記動脈が冠動脈または末梢動脈である、請求項7に記載の組成物。
- 前記動脈が、腎動脈、脳動脈、肺動脈、および脚の動脈からなる群から選択される、請求項7に記載の組成物。
- 前記動脈が肺動脈である、請求項9に記載の組成物。
- 前記血管が静脈である、請求項1から6のいずれか一項に記載の組成物。
- 前記組成物が、約0.001mg〜約100mgの用量で投与されることを特徴とする、請求項1から11のいずれか一項に記載の組成物。
- 前記組成物が、約0.05mg〜約5mgの用量で投与されることを特徴とする、請求項12に記載の組成物。
- 前記組成物の注射量が、約0.01ml〜約50mlであることを特徴とする、請求項1から13のいずれか一項に記載の組成物。
- 前記組成物の前記注射量が、約0.5ml〜約5mlであることを特徴とする、請求項14に記載の組成物。
- 前記組成物が、針付きカテーテルを通して注射されることを特徴とする、請求項1から15のいずれか一項に記載の組成物。
- 前記組成物が、少なくとも年1回投与されることを特徴とする、請求項1から16のいずれか一項に記載の組成物。
- 前記組成物が、疾患部位の遠位または近位に注射されることを特徴とする、請求項1から17のいずれか一項に記載の組成物。
- 前記組成物が、疾患部位から少なくとも約2cm離れた場所に注射されることを特徴とする、請求項1から17のいずれか一項に記載の組成物。
- 前記組成物が、疾患部位に、または疾患部位に隣接して注射されることを特徴とする、請求項1から17のいずれか一項に記載の組成物。
- 前記個体が、狭心症、心筋梗塞、うっ血性心不全、心不整脈、末梢動脈疾患、跛行、または慢性肢虚血のうちのいずれか1つを有する、請求項1から20のいずれか一項に記載の組成物。
- アルブミンおよびラパマイシンを含むナノ粒子を含む、血管に送達するための組成物であって、有効量の該組成物が、血管壁内への注射によって個体に投与されることを特徴とする、組成物。
- 前記組成物が、針付きカテーテルを介して注射されることを特徴とする、請求項22に記載の組成物。
- 前記組成物中の前記ナノ粒子が、約200nm以下のアベレージ直径を有する、請求項1から23のいずれか一項に記載の組成物。
- 前記組成物中の前記ナノ粒子が、約100nm以下のアベレージ直径を有する、請求項24に記載の組成物。
- 前記組成物中の前記ナノ粒子が、約70nm以上のアベレージ直径を有する、請求項25に記載の組成物。
- 前記ナノ粒子中の前記ラパマイシンが、アルブミンで被覆されている、請求項1から26のいずれか一項に記載の組成物。
- 前記個体がヒトである、請求項1から27のいずれか一項に記載の組成物。
- 前記組成物が血管介入手順中に使用されることを特徴とする、請求項1から28のいずれか一項に記載の組成物。
- 前記組成物が血管介入手順後に使用されることを特徴とする、請求項1から28のいずれか一項に記載の組成物。
- 前記介入手順が、血管形成術、ステント留置術、またはアテローム切除術である、請求項29または30に記載の組成物。
- 針付きカテーテルであって、該針が、ラパマイシンおよびアルブミンを含むナノ粒子を含む組成物を含有し、該組成物が、血管壁内への注射によって投与されることを特徴とする、カテーテル。
- 前記組成物中の前記ナノ粒子が、約200nm以下のアベレージ直径を有する、請求項32に記載のカテーテル。
- 前記組成物中の前記ナノ粒子が、約100nm以下のアベレージ直径を有する、請求項33に記載のカテーテル。
- 前記組成物中の前記ナノ粒子が、約70nm以上のアベレージ直径を有する、請求項34に記載のカテーテル。
- 前記ナノ粒子が、アルブミンで被覆された前記ラパマイシンを含む、請求項32から35のいずれか一項に記載のカテーテル。
- 前記針が展開可能である、請求項32から36のいずれか一項に記載のカテーテル。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161518084P | 2011-04-28 | 2011-04-28 | |
US61/518,084 | 2011-04-28 | ||
US201161557851P | 2011-11-09 | 2011-11-09 | |
US61/557,851 | 2011-11-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508146A Division JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017157942A Division JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017002083A JP2017002083A (ja) | 2017-01-05 |
JP2017002083A5 true JP2017002083A5 (ja) | 2017-02-16 |
JP6196719B2 JP6196719B2 (ja) | 2017-09-13 |
Family
ID=47072793
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508146A Active JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
JP2016196955A Active JP6196719B2 (ja) | 2011-04-28 | 2016-10-05 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
JP2017157942A Active JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508146A Active JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017157942A Active JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Country Status (14)
Country | Link |
---|---|
US (5) | US9061014B2 (ja) |
EP (1) | EP2701731B1 (ja) |
JP (4) | JP6038123B2 (ja) |
KR (3) | KR101970342B1 (ja) |
CN (3) | CN103648521A (ja) |
AU (2) | AU2012249371B2 (ja) |
BR (1) | BR112013027674A2 (ja) |
CA (2) | CA3063641A1 (ja) |
ES (1) | ES2819204T3 (ja) |
IL (2) | IL229041B (ja) |
MX (1) | MX354216B (ja) |
SG (2) | SG194623A1 (ja) |
WO (1) | WO2012149451A1 (ja) |
ZA (1) | ZA201307875B (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US10441747B2 (en) | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
CN101076290B (zh) | 2004-12-09 | 2011-11-23 | 铸造品股份有限公司 | 主动脉瓣修复 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
PL3248600T3 (pl) | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
AU2012201568B2 (en) * | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
HUE047376T2 (hu) | 2009-04-15 | 2020-04-28 | Abraxis Bioscience Llc | Prionmentes nanorészecske-készítmények és elõállításuk |
EP2421364A4 (en) | 2009-04-22 | 2012-10-17 | Mercator Medsystems Inc | USE OF GUANETHIDINE FOR THE TREATMENT OF HYPERTENSION BY LOCAL VASCULAR DELIVERY |
LT2552438T (lt) | 2010-03-26 | 2016-09-26 | Abraxis Bioscience, Llc | Hepatoceliulinės karcinomos gydymo būdai |
KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
SG186112A1 (en) | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
US20120259269A1 (en) | 2011-04-08 | 2012-10-11 | Tyco Healthcare Group Lp | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP2968254B1 (en) | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
KR20150127187A (ko) | 2013-03-14 | 2015-11-16 | 아브락시스 바이오사이언스, 엘엘씨 | 방광암의 치료 방법 |
WO2016065245A1 (en) | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
AU2016285720C1 (en) | 2015-06-29 | 2022-02-03 | Abraxis Bioscience, Llc | Methods of treating epithelioid cell tumors |
CN109996549A (zh) * | 2016-09-22 | 2019-07-09 | 墨卡托医疗系统公司 | 使用坦罗莫司治疗再狭窄 |
EA201990820A1 (ru) * | 2016-09-28 | 2019-10-31 | Способы лечения митохондриальных и метаболических нарушений | |
CN110996687A (zh) | 2017-05-26 | 2020-04-10 | 墨卡托医疗系统公司 | 用于治疗再狭窄的联合疗法 |
US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
CN111760174B (zh) | 2018-03-14 | 2023-08-25 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械和医疗方法 |
SG11202009145PA (en) | 2018-03-20 | 2020-10-29 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
JP7335123B2 (ja) * | 2019-10-07 | 2023-08-29 | 株式会社日本触媒 | 樹脂組成物、硬化性組成物、塗膜付き物品、塗膜付き物品の製造方法、コーティング剤及び積層塗膜付き基材の製造方法 |
MX2022004989A (es) | 2019-10-28 | 2022-07-21 | Abraxis Bioscience Llc | Composiciones farmaceuticas de albumina y rapamicina. |
WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
CN1331321A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人丝/苏氨酸蛋白激酶16.17和编码这种多肽的多核苷酸 |
ATE481097T1 (de) | 2001-01-16 | 2010-10-15 | Vascular Therapies Llc | Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate |
US6547303B1 (en) | 2001-08-13 | 2003-04-15 | Johnson Controls Technology Company | Pivoting seating system |
US6860867B2 (en) | 2001-09-20 | 2005-03-01 | The Regents Of The University Of California | Method of interventional surgery |
WO2003061731A2 (en) | 2002-01-22 | 2003-07-31 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
US7744584B2 (en) | 2002-01-22 | 2010-06-29 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
US20060189941A1 (en) * | 2002-01-22 | 2006-08-24 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
DE10244847A1 (de) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
CA2497349C (en) * | 2002-09-26 | 2008-07-08 | Angiotech International Ag | Perivascular wraps |
AU2003299590B8 (en) | 2002-12-09 | 2010-04-08 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
US20040213770A1 (en) | 2003-04-22 | 2004-10-28 | Endobionics, Inc. | Methods and systems for treating ischemic cardiac and other tissues |
US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US20090204104A1 (en) | 2004-05-13 | 2009-08-13 | Medtronic Vascular, Inc | Methods for Compounding and Delivering a Therapeutic Agent to the Adventitia of a Vessel |
AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
US7727554B2 (en) * | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
PL3248600T3 (pl) | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
BRPI0610818A2 (pt) | 2005-05-16 | 2010-07-27 | Novartis Ag | uso de derivados de rapamicina para o tratamento e/ou para a prevenção de distúrbios cardiovasculares |
US20090035346A1 (en) | 2005-06-21 | 2009-02-05 | Pervasis Therpeutics, Inc. | Methods and Compositions for Enhancing Vascular Access |
JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス, エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
JP2010511595A (ja) * | 2006-07-31 | 2010-04-15 | ニューロシステック コーポレイション | 遊離塩基ガシクリジンナノ粒子 |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
PL2481402T3 (pl) | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
US9044385B2 (en) * | 2007-05-16 | 2015-06-02 | Abbott Cardiovascular Systems Inc. | Therapeutic compositions for targeted vessel delivery |
JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス, エルエルシー | 再発性癌の処置のための方法および組成物 |
US8728528B2 (en) * | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
WO2009126401A1 (en) | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
WO2010068925A1 (en) | 2008-12-11 | 2010-06-17 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
EP2405750B1 (en) | 2009-03-13 | 2018-05-09 | Abraxis BioScience, LLC | Combination therapy with thiocolchicine derivatives |
ES2788298T3 (es) | 2009-04-10 | 2020-10-21 | Abraxis Bioscience Llc | Formulaciones de nanopartículas y usos de las mismas |
HUE047376T2 (hu) | 2009-04-15 | 2020-04-28 | Abraxis Bioscience Llc | Prionmentes nanorészecske-készítmények és elõállításuk |
EP2421364A4 (en) * | 2009-04-22 | 2012-10-17 | Mercator Medsystems Inc | USE OF GUANETHIDINE FOR THE TREATMENT OF HYPERTENSION BY LOCAL VASCULAR DELIVERY |
DK2470173T3 (en) | 2009-08-25 | 2016-06-06 | Abraxis Bioscience Llc | Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors |
LT2552438T (lt) | 2010-03-26 | 2016-09-26 | Abraxis Bioscience, Llc | Hepatoceliulinės karcinomos gydymo būdai |
NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
US9096660B2 (en) * | 2010-04-26 | 2015-08-04 | Abraxis Bioscience, Llc | SPARC binding antibodies and uses thereof |
RU2621640C2 (ru) | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
SG186112A1 (en) | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
JP6031437B2 (ja) | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス, エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
CN103648521A (zh) * | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP2968254B1 (en) | 2013-03-12 | 2020-04-22 | Abraxis BioScience, LLC | Methods of treating lung cancer |
WO2014143613A1 (en) | 2013-03-13 | 2014-09-18 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
KR20150127187A (ko) | 2013-03-14 | 2015-11-16 | 아브락시스 바이오사이언스, 엘엘씨 | 방광암의 치료 방법 |
WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
CA2990703C (en) | 2015-06-29 | 2024-04-30 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
JP2018521058A (ja) | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス, エルエルシー | ナノ粒子mTOR阻害剤併用治療を使用して固形腫瘍を処置する方法 |
KR20180019231A (ko) | 2015-06-29 | 2018-02-23 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 mTOR 억제제 조합 요법을 사용하여 혈액 악성종양을 치료하는 방법 |
AU2016285720C1 (en) | 2015-06-29 | 2022-02-03 | Abraxis Bioscience, Llc | Methods of treating epithelioid cell tumors |
US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2012
- 2012-04-27 CN CN201280032010.2A patent/CN103648521A/zh active Pending
- 2012-04-27 CN CN201811222358.3A patent/CN109288789A/zh active Pending
- 2012-04-27 AU AU2012249371A patent/AU2012249371B2/en active Active
- 2012-04-27 WO PCT/US2012/035626 patent/WO2012149451A1/en active Application Filing
- 2012-04-27 JP JP2014508146A patent/JP6038123B2/ja active Active
- 2012-04-27 CA CA3063641A patent/CA3063641A1/en not_active Abandoned
- 2012-04-27 SG SG2013079264A patent/SG194623A1/en unknown
- 2012-04-27 US US14/113,568 patent/US9061014B2/en active Active
- 2012-04-27 CA CA2834040A patent/CA2834040C/en active Active
- 2012-04-27 CN CN201810882369.8A patent/CN109172809A/zh active Pending
- 2012-04-27 KR KR1020137031161A patent/KR101970342B1/ko active IP Right Grant
- 2012-04-27 BR BR112013027674A patent/BR112013027674A2/pt not_active Application Discontinuation
- 2012-04-27 EP EP12777153.3A patent/EP2701731B1/en active Active
- 2012-04-27 ES ES12777153T patent/ES2819204T3/es active Active
- 2012-04-27 SG SG10201606406PA patent/SG10201606406PA/en unknown
- 2012-04-27 KR KR1020197010659A patent/KR102108959B1/ko active IP Right Grant
- 2012-04-27 KR KR1020207012800A patent/KR20200051841A/ko not_active Application Discontinuation
- 2012-04-27 MX MX2013012458A patent/MX354216B/es active IP Right Grant
-
2013
- 2013-10-22 ZA ZA2013/07875A patent/ZA201307875B/en unknown
- 2013-10-24 IL IL229041A patent/IL229041B/en active IP Right Grant
-
2015
- 2015-05-15 US US14/714,131 patent/US9884013B2/en active Active
-
2016
- 2016-10-05 JP JP2016196955A patent/JP6196719B2/ja active Active
-
2017
- 2017-08-18 JP JP2017157942A patent/JP6427641B2/ja active Active
- 2017-09-06 AU AU2017225031A patent/AU2017225031B2/en active Active
- 2017-12-21 US US15/851,478 patent/US10258565B2/en active Active
-
2018
- 2018-10-29 JP JP2018203038A patent/JP2019011378A/ja active Pending
-
2019
- 2019-02-25 US US16/284,995 patent/US20190183789A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272313A patent/IL272313A/en unknown
- 2020-06-12 US US16/900,565 patent/US20200306180A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017002083A5 (ja) | ||
JP2014515028A5 (ja) | ||
de Gregorio et al. | Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease | |
Taguchi et al. | Effects of enhanced external counterpulsation on hemodynamics and its mechanism relation to neurohumoral factors | |
JP2019206562A5 (ja) | ||
JP2015518897A5 (ja) | ||
Faxon et al. | Interventional cardiology: current status and future directions in coronary disease and valvular heart disease | |
JP2020521755A5 (ja) | ||
Ateş et al. | Acute coronary syndrome due to midazolam use: Kounis syndrome during a transurethral prostatectomy | |
Colucci | Overview of the therapy of heart failure due to systolic dysfunction | |
Dvir et al. | Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor® for Myocardial Infarction Registry) | |
CN104000809B (zh) | 一种防治冠心病心绞痛的药物组合物及其应用 | |
Monopoli et al. | Acute myocardial infarction with occlusion of all three main epicardial coronary arteries: when Mother Nature takes care more than physicians | |
Quan et al. | Acute left heart failure caused by Takayasu arteritis: a case report and literature review | |
Keskin et al. | An unexpected complication of acute pancreatitis: Intra-cardiac thrombus | |
Wei et al. | Giant right sinus of Valsalva aneurysm led to proximal right coronary artery occlusion. | |
Park et al. | Use of non-vitamin k dependent oral anticoagulant in ischemic stroke | |
Hardy et al. | Intra-aortic balloon pump entrapment and surgical removal: a case report | |
Yamada et al. | Reply to letter to the editor:“A potential and lionhearted soldier for atrial fibrillation accompanied with heart failure: Renal denervation” | |
CN202843855U (zh) | 一种新型冠状动脉血管支架 | |
Kılıç et al. | A severe aortic coarctation newly diagnosed during cardiac catheterization in an adult presenting with acute anterior myocardial infarction | |
Kusunose | Report of the American College of Cardiology (ACC) scientific sessions 2014, Washington, DC | |
Biyik | Mycophenolate mofetil/tacrolimus | |
Karabay et al. | Coronary muscular bridge mimicking acute stent thrombosis: online article | |
Özmen et al. | Frequently occurring torsades de pointes attacks in an old patient on solifenacin therapy and management strategy |